| Followers | 35 |
| Posts | 1908 |
| Boards Moderated | 0 |
| Alias Born | 11/05/2020 |
Tuesday, May 17, 2022 9:05:57 PM
Moving the goal posts isn't going to work. It's a whole new ball game.
You don't default on a toxic loan with nothing to show for it and then think when it's all "cleaned up" it will make the company move on.
This is a clear indication that there is no money. How can the company move forward without taking out another loan?
He took a $117,000 to hire his brother for something that is ridiculous and was "supposedly" already contracted out to do with another firm.
You have money to pay your brother like that but don't have money to manage a toxic loan? It was $1.5 million. Where did that money go? How can you not pay off at least one month of that loan using that same loan money? It's a clear indication of something nefarious.
This isn't hard. It's finance 101.
The fact that he took a toxic loan and hired his brother are major red flags.
A company that has sound science that's been around for years and years wouldn't need to do any of these things.
It says all that needs to be said.
You don't default on a toxic loan with nothing to show for it and then think when it's all "cleaned up" it will make the company move on.
This is a clear indication that there is no money. How can the company move forward without taking out another loan?
He took a $117,000 to hire his brother for something that is ridiculous and was "supposedly" already contracted out to do with another firm.
You have money to pay your brother like that but don't have money to manage a toxic loan? It was $1.5 million. Where did that money go? How can you not pay off at least one month of that loan using that same loan money? It's a clear indication of something nefarious.
This isn't hard. It's finance 101.
The fact that he took a toxic loan and hired his brother are major red flags.
A company that has sound science that's been around for years and years wouldn't need to do any of these things.
It says all that needs to be said.
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
